Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$6.20 USD
-0.14 (-2.21%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.22 +0.02 (0.32%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Cullinan Therapeutics, Inc. has a market cap of $374.53M, which represents its share price of $6.34 multiplied by its outstanding shares number of 59.07M. As a small-cap company, CGEM's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CGEM 6.20 -0.14(-2.21%)
Will CGEM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGEM
180 Bearish Setup appears for CGEM after 2.21% move
CGEM forms Stochastic Buy Signal on September 18
Is CGEM signaling selling opportunity? New 52 Week Closing Low shows up after crashing 5.72%
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc
New 52 Week Closing Low appears for CGEM after 0.94% move